After a Strong Quarterly Result, Is It Finally Safe to Buy Pfizer Stock Again?

Pfizer (NYSE: PFE) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID vaccine resulted in the business posting record sales and profits in 2022. But then, as things went back to normal and demand diminished for its vaccine, so too did interest in Pfizer's stock.What's startling, however, is the stock hasn't simply gone back to the levels it was at back before the pandemic -- it has been on a full-blown crash. Since 2023, the healthcare stock has lost more than half of its value. This year, it's reached levels it hasn't seen in 13 years. It seems like a steal of a deal. Except, no one is in a rush to buy Pfizer's stock. Investors are concerned about what lies ahead for the business and there are many question marks about its future growth. Recently, the company released some positive earnings numbers. Could they mark a turning point for this struggling stock, and could now be a good time to invest in Pfizer?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool